IMNN stock has a bullish outlook due to its strong growth potential. Analysts project a significant upside, with EF Hutton setting a price target of $10.71, representing a 939.81% increase from its current price of $1.03, driven by positive Phase 2 trial results and institutional interest. Additionally, D. Boral Capital maintains a "Strong Buy" rating with an ambitious $29 target, reflecting confidence in the company's innovative cancer therapies and upcoming Phase 3 trials.